US 11,730,820 B2
Peptidic blocks for nucleic acid delivery
Seyed Moien Moghimi, København (DK); Linping Wu, Søborg (DK); Davoud Ahmadvand, Søborg (DK); and Ladan Parhamifar, Fredriksberg (DK)
Assigned to S. M. Discovery Group Inc., Centennial, CO (US)
Filed by S. M. Discovery Group Inc., Centennial, CO (US)
Filed on Apr. 2, 2021, as Appl. No. 17/301,430.
Application 17/301,430 is a continuation of application No. 15/991,738, filed on May 29, 2018, granted, now 11,000,599.
Application 15/991,738 is a continuation of application No. 14/912,997, granted, now 9,981,047, issued on May 29, 2018, previously published as PCT/EP2014/067651, filed on Aug. 19, 2014.
Claims priority of application No. PA 2013 70453 (DK), filed on Aug. 19, 2013.
Prior Publication US 2021/0290773 A1, Sep. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/66 (2017.01); A61K 47/69 (2017.01); A61K 49/00 (2006.01); A61K 47/64 (2017.01); C12N 15/113 (2010.01)
CPC A61K 47/66 (2017.08) [A61K 47/64 (2017.08); A61K 47/69 (2017.08); A61K 47/6901 (2017.08); A61K 47/6911 (2017.08); A61K 47/6929 (2017.08); A61K 47/6953 (2017.08); A61K 49/0002 (2013.01); A61K 49/0056 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3513 (2013.01)] 13 Claims
 
1. A therapeutic composition, comprising:
a peptide segment which is SEQ ID NO. 2 and pharmaceutically acceptable salts or esters thereof; and
a cysteine residue at the N-terminus or C-terminus of the peptide segment.